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Poster Session I S249relative orMatchedRelatedDonor (MRD). From1990 to 2007, a to-
tal of 15 pediatric or young adult patients with MDS received bone
marrow or cord blood transplant from an HLA matched sibling at
our institution. M:F ratio of the study group was 0.9; Two patients
belonged to ethnic minorities (13%); the median age at transplant
was 13.4 years (range 1.1-20.6) and median weight was 54.9 kg
(range 10.8-80.2). Three patients had therapy-related MDS (2
ALL, 1 NHL). MDS stage was RA/RC in 2 pts, RARS in 1 pt,
RAEB in 6 pts, RAEB-T in 2 pts, and AML in 4 pts. Monosomy 7
was present in 4 (27%) pts. Median time from diagnosis to transplant
was 3 months (range 1.3-25.8). Preparative regimen was non-TBI
based in 13 (87%) pts. TBI was used for 2 of the patients with
AML. Fourteen (93%) patients received melphalan. Cyclosporine
was used for GVHD prophylaxis with methotrexate in 12 pts and
Solu-medrol in 2 pts. The grafts (14 BM, 1UCB) contained amedian
of 2  10e8 (range 0.7-8.4) nucleated cells/kg infused. All patients
achieved neutrophil engraftment. Median time to neutrophil recov-
ery (ANC. 500) was 17 days (range 10-33), and that to platelet re-
covery (.50 K untransfused) was 43 days (range 21-150). Acute
GVHD, grade II-IV, was seen in 6 (40%) patients; none of the pa-
tients had grade III-IV acute GVHD. Chronic GVHD was seen in
4 (27%) patients, 2 limited (skin), and 2 extensive (skin, gut). The
only patient with RARS died from lactic acidosis secondary to
MELAS syndrome diagnosed post mortem. One patient, who had
undergone a prior transplant for ALL, acquired monosomy 7 clone
40months later. She underwent BMT from the same donor, relapsed
again after 22 months, underwent a third successful transplant from
the same donor with non-myeloablative conditioning and peripheral
blood stem cells. She is disease free 8 years from the last transplant.
Thus, 14 (93.3%) of the 15 patients are surviving long term and dis-
ease free with a median follow-up of 8.5 years (range 2.3-19). Bone
marrow or cord blood transplant from matched related donor with
non-TBI based, melphalan containing regimen is very effective in
curing MDS affecting children and young adults.244
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Lymphocyte receptor generation requires proteins in the DNA-
double strand break (DNA-dsb) repair and non-homologous end-
joining pathway. Nibrin senses DNA-dsb, DNA ligase IV (LIG4)
and Cernunnos-XRCC4-like factor (C-XLF) ligate DNA-dsb to
form lymphocyte receptors, as well as general DNA-dsb repair. De-
ficiency of these enzymes confers radiosensitivity (RS) and primary
immunodeficiency (PID). Patients with PID due to deficiencies in
these genes are increasingly offered HSCT. Many conditioning reg-
imens (CR) damage DNA and RS patients die from CR toxicity; less
toxic CR are required to successfully treat these patients. We report
3 microcephalic RS patients treated using a modified Fanconi anae-
mia CR of C-1H 0.2 mg/KgD-9 –D-5, fludarabine 30 mg/m2D-9 –
D-5, cyclophosphamide 5 mg/kg D-5-D-2.
Patient 1 presented with prolonged RSV excretion. She had pan-
lymphopenia with marked CD8 lymphopenia, reduced PHA re-
sponse andpan-hypogammaglobulinaemiawith poor vaccine antigen
antibody responses. A homozygous 1089C.A mutation in NBS1
confirmed Nijmegen breakage syndrome. She underwent HLA-
identical sibling HSCT age 2 years. At 5 years post-HSCT she has
stable mixed donor chimerism in all cell lineages, with normal lym-
phocyte numbers and antibody responses to vaccine antigens.
Patient 2 presented with failure to thrive, persistent diarrhoea, re-
current respiratory infection and severe lymphopenia with hypogam-
maglobulinaemia. She had a homozygous c.833 G.A LIG4
mutation. She underwent a 9/10 (Amm) HLAmis-matched parental
HSCT aged 4.5 years. CSA and MMF were used as GvHD prophy-
laxis. Initial donor chimerism was 12%, but by 1 year post-HSCT
was 100% with full immunoreconstitution.
Patient 3 presentedwith developmental delay, severe lymphopenia
and hypogammaglobulinaemia, recurrent respiratory infection andcytomegaloviremia (CMV). He had a homozygous c.169C.Tmu-
tation in NHEJ1, confirming C-XLF deficient PID. He underwent
9/10 (Amm) HLA-mis-matched URD HSCT aged 3.5 years. CSA
andMMF were used as GvHD prophylaxis. Initial donor chimerism
was 25%, but by 2months postHSCTwas 100%.There was no con-
ditioning-related toxicity and immunoreconstitution at 4 months
was 100% donor. Subsequent complications included CMV reacti-
vation and skin and liver GvHD, from which he died at 358 days
post-HSCT. These, and a survey of other cases, demonstrate safety
and efficacy of this conditioning protocol. Further studies will be re-
quired to assess the long term outcome.245
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Intensive chemotherapy dependent on autologous stem cell trans-
plants (ASCT) is used in many protocols for solid tumors, including
brain tumors, and leukemias. ASCT allow the use of more intensive
chemotherapy and faster neutrophil and platelet recovery. Previous
studies have shown that the time to engraftment ranges from 9-28
days for neutrophils (ANC. 500/microliter). ASCT may also be
followed by engraftment toxicity, including fever, sepsis, shock,
and in rare instances, death. Between January 2001 and June 2009,
92 brain tumor, neuroblastoma, and primitive neuro-ectodermal tu-
mor patients (age 6 months to 27 years at transplant) underwent 186
peripheral blood ASCT at Children’s National Medical Center.
Multivariate analysis was used to determine variables affecting pa-
tient outcome measures (time to engraftment, transplant toxicity,
and time to pre-harvest absolute CD34+ peak). Transplant toxicity
was scored on an ordinal scale based on the severity of transplant-re-
lated complications. Independent variables analyzed included vari-
ables that were patient specific (age, weight, tumor type,
chemotherapy administered, and primary vs relapsed disease) and
those related to the harvest or transplant (WBC and CD34+ counts
prior to transplant and quantity of total nucleated cells and CD34+
cells infused during transplant). All cell counts were normalized to
patient weight.
Results:The time to engraftment post transplant was positively cor-
related with absolute CD34+ cells transfused (p5 0.01) and had
a less significant correlation with totalWBC and CD34% transfused
(p5 0.09). No significant correlation was found between platelet re-
covery and quantity of WBC or CD34+ cells transfused. Transplant
toxicity was significantly less with increasing with CD34+ and
CD34%, and was significantly greater in neuroblastoma patients.
The toxicity was significantly greater in younger patients. The
time to CD34+ recovery pre-harvest was significantly affected by pa-
tient diagnosis, chemotherapy regimen, and primary versus recur-
rent disease.
Conclusions: Infusion of larger numbers of CD34+ cells decreased
time to engraftment and transplant toxicity. In this pediatric popula-
tion, neuroblastoma patients and younger patients had more trans-
plant toxicity.246
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SICKLE CELL DISEASE PATIENTS TO TECHNOLOGIES THAT FACILITATE
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Children who receive hematopoietic cell transplantation (HCT)
for sickle cell disease (SCD) from an HLA-matched, SCD-free sib-
ling show disease-free survival of at least 85%, yet the majority of
children with SCD do not undergo HCT.
